Anthera Raises $33M After Stock Bump on Lupus Data

After getting hammered a month ago on news of a missed primary endpoint in the Phase IIb PEARL-SC study of lupus drug blisibimod, shares of Anthera Pharmaceuticals Inc. rebounded last week when the Hayward, Calif.-based firm released promising data from a subset of patients in the study.